Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Stalmack Kathryn

2. Date of Event Requiring Statement (MM/DD/YYYY) 8/6/2018

3. Issuer Name and Ticker or Trading Symbol

BioScrip, Inc. [BIOS]

(Last) (First) (Middle)

C/O BIOSCRIP, INC., 1600 BROADWAY, SUITE 700

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
General Counsel /

(Street)

DENVER, CO 80202

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $.0001 Par Value	20000	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	8/10/2025	Common Stock, $.0001 Par Value	125000	$2.08	D
Employee Stock Option (Right to Buy)	⁽¹⁾	2/9/2027	Common Stock, $.0001 Par Value	99010	$1.63	D
Employee Stock Option (Right to Buy)	⁽¹⁾	3/15/2027	Common Stock, $.0001 Par Value	77519	$2.08	D
Restricted Stock Unit	⁽²⁾	⁽²⁾	Common Stock, $.0001 Par Value	73745	⁽³⁾	D
Employee Stock Option (Right to Buy)	⁽¹⁾	4/11/2028	Common Stock, $.0001 Par Value	45684	$2.59	D
Restricted Stock Unit	⁽²⁾	⁽²⁾	Common Stock, $.0001 Par Value	29527	⁽³⁾	D

Explanation of Responses:
(1)	Vests and becomes exercisable in three equal annual installments commencing on the first anniversary of the date of grant.
(2)	The Restricted Stock Units vest in three equal annual installments commencing on the first anniversary of the date of grant.
(3)	Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Stalmack Kathryn C/O BIOSCRIP, INC. 1600 BROADWAY, SUITE 700 DENVER, CO 80202			General Counsel

Signatures
/s/ Kathryn Stalmack		8/14/2018
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.